CSOWM PRACTICE EXAM 2026 STUDY
PAPER QUESTIONS AND CORRECT
DETAILED ANSWERS VERIFIED A+
⩥ cholecystokinin. Answer: a hormone that is secreted by cells in the
duodenum and stimulates the release of bile into the intestine and the
secretion of enzymes by the pancreas; decreases appetite.
⩥ Gastric inhibitory polypeptide. Answer: Hormone, released by
intestine; Inhibits gastric secretion and motility and potentiates release of
insulin from beta cells in response to elevated blood glucose
concentration. stimulated by Presence of fat and glucose in the small
intestine; promotes satiety
⩥ Glucagon-like peptide 1 (GLP-1). Answer: substance released by the
intestines (ileum) in response to glucose, FA and fiber and travels to the
brain- terminates eating; inhibits gastric secretion and glucagon
secretion and enhances insulin secretion
⩥ Ghrelin. Answer: hormone secreted by empty stomach; sends "I'm
hungry" signals to the brain; increases with time since last feeding
⩥ Leptin. Answer: protein hormone secreted by fat cells; when
abundant, causes brain to increase metabolism and decrease hunger;
elevated in overweight/obese (leptin resistant)
,⩥ hormonal response to weight loss. Answer: increased ghrelin and
reduced PYY, CCK, leptin, insulin; may persist >1 yr and lead to
increased cal intake leading to weight regain
⩥ phentermine/topiramate (qsymia) dosage. Answer: 3.75/23mg per day
x 2 weeks then increase to 7.5/46mg per day; max dose 15/92mg only if
pts have not lost >5% BW in 12 weeks (taper gradually DT increased
risk seizure)
⩥ phentermine/topiramate mechanism. Answer: stimulates
norepinephrine in hypothal leading to appetite suppression
⩥ phentermine/topiramate side effects. Answer: insomnia, dry mouth,
constipation, paraesthesia, dizziness, dysgeusia
⩥ phentermine/topiramate contraindications. Answer: hyperthyroid;
glaucoma, MAO inhibitor, sympathomimetic amines
⩥ orlistat (xenical) dosage. Answer: prescription 120mg tid; OTC 60mg
tid during or <1hr after meal with fat
⩥ orlistat mechanism of action. Answer: inhibits gastric and pancreatic
lipase
,⩥ orlistat side effects. Answer: steatorrhea, fecal incontinence, decreased
absorption of fat soluble vitamins
⩥ Orlistat contraindications. Answer: Pregnancy, chronic malabsorption
syndrome, cholestasis
⩥ Lorcaserin (Belviq) dosage. Answer: 10 mg bid; DC if <5% weight
loss by 12 weeks
⩥ Lorcaserin mechanism of action. Answer: 5HT2c receptor agonist
(binding site for serotonin; mood, feeding, reproduction, anxiety);
increases satiety
⩥ lorcaserin side effects. Answer: dry mouth, fatigue, constipation,
hypoglycemia (in DM)
⩥ Lorcaserin contraindications. Answer: pts on SSRI or SNRI (increased
risk serotonin syndrome), pregnancy, breastfeeding
⩥ Naltrexone/Bupropion (Contrave) dosage. Answer: 8/90mg (add 1
tablet each week until reach max dose 4/d= 32/360mg); DC use if <5%
BW lost in 12 wks
, ⩥ naltrexone/bupropion mechanism of action. Answer: reuptake
inhibitor of dopamine and norepinephrine (bupropion) and opioid
antagonist (naltrexone) leading to decreased appetite and cravings
⩥ naltrexone/bupropion side effects. Answer: N/V, constipation,
headache, dizziness
⩥ naltrexone/bupropion contraindications. Answer: uncontrolled HTN;
seizure disorders; AN/BN; drug/alcohol addictions or withdrawal
⩥ Liraglutide (saxenda) dosage. Answer: 3 mg injectable (1.8mg for
DM)
⩥ Liraglutide mechanism of action. Answer: Analog of human GLP-1
that causes direct activation of GLP-1 receptors. Slows gastric emptying,
stimulates glucose-dependent insulin release, and inhibits release of
glucagon.
⩥ Liraglutide side effects. Answer: N/V; pancreatitis; increased HR
⩥ Liraglutide Contraindications. Answer: Hx of medullary thyroid
cancer
PAPER QUESTIONS AND CORRECT
DETAILED ANSWERS VERIFIED A+
⩥ cholecystokinin. Answer: a hormone that is secreted by cells in the
duodenum and stimulates the release of bile into the intestine and the
secretion of enzymes by the pancreas; decreases appetite.
⩥ Gastric inhibitory polypeptide. Answer: Hormone, released by
intestine; Inhibits gastric secretion and motility and potentiates release of
insulin from beta cells in response to elevated blood glucose
concentration. stimulated by Presence of fat and glucose in the small
intestine; promotes satiety
⩥ Glucagon-like peptide 1 (GLP-1). Answer: substance released by the
intestines (ileum) in response to glucose, FA and fiber and travels to the
brain- terminates eating; inhibits gastric secretion and glucagon
secretion and enhances insulin secretion
⩥ Ghrelin. Answer: hormone secreted by empty stomach; sends "I'm
hungry" signals to the brain; increases with time since last feeding
⩥ Leptin. Answer: protein hormone secreted by fat cells; when
abundant, causes brain to increase metabolism and decrease hunger;
elevated in overweight/obese (leptin resistant)
,⩥ hormonal response to weight loss. Answer: increased ghrelin and
reduced PYY, CCK, leptin, insulin; may persist >1 yr and lead to
increased cal intake leading to weight regain
⩥ phentermine/topiramate (qsymia) dosage. Answer: 3.75/23mg per day
x 2 weeks then increase to 7.5/46mg per day; max dose 15/92mg only if
pts have not lost >5% BW in 12 weeks (taper gradually DT increased
risk seizure)
⩥ phentermine/topiramate mechanism. Answer: stimulates
norepinephrine in hypothal leading to appetite suppression
⩥ phentermine/topiramate side effects. Answer: insomnia, dry mouth,
constipation, paraesthesia, dizziness, dysgeusia
⩥ phentermine/topiramate contraindications. Answer: hyperthyroid;
glaucoma, MAO inhibitor, sympathomimetic amines
⩥ orlistat (xenical) dosage. Answer: prescription 120mg tid; OTC 60mg
tid during or <1hr after meal with fat
⩥ orlistat mechanism of action. Answer: inhibits gastric and pancreatic
lipase
,⩥ orlistat side effects. Answer: steatorrhea, fecal incontinence, decreased
absorption of fat soluble vitamins
⩥ Orlistat contraindications. Answer: Pregnancy, chronic malabsorption
syndrome, cholestasis
⩥ Lorcaserin (Belviq) dosage. Answer: 10 mg bid; DC if <5% weight
loss by 12 weeks
⩥ Lorcaserin mechanism of action. Answer: 5HT2c receptor agonist
(binding site for serotonin; mood, feeding, reproduction, anxiety);
increases satiety
⩥ lorcaserin side effects. Answer: dry mouth, fatigue, constipation,
hypoglycemia (in DM)
⩥ Lorcaserin contraindications. Answer: pts on SSRI or SNRI (increased
risk serotonin syndrome), pregnancy, breastfeeding
⩥ Naltrexone/Bupropion (Contrave) dosage. Answer: 8/90mg (add 1
tablet each week until reach max dose 4/d= 32/360mg); DC use if <5%
BW lost in 12 wks
, ⩥ naltrexone/bupropion mechanism of action. Answer: reuptake
inhibitor of dopamine and norepinephrine (bupropion) and opioid
antagonist (naltrexone) leading to decreased appetite and cravings
⩥ naltrexone/bupropion side effects. Answer: N/V, constipation,
headache, dizziness
⩥ naltrexone/bupropion contraindications. Answer: uncontrolled HTN;
seizure disorders; AN/BN; drug/alcohol addictions or withdrawal
⩥ Liraglutide (saxenda) dosage. Answer: 3 mg injectable (1.8mg for
DM)
⩥ Liraglutide mechanism of action. Answer: Analog of human GLP-1
that causes direct activation of GLP-1 receptors. Slows gastric emptying,
stimulates glucose-dependent insulin release, and inhibits release of
glucagon.
⩥ Liraglutide side effects. Answer: N/V; pancreatitis; increased HR
⩥ Liraglutide Contraindications. Answer: Hx of medullary thyroid
cancer
